标签： 上海龙凤1314

Nowadays, the first thing for consumers to buy a car is to see whether this car is rich in configuration, and it is no exception to nature. Next, let’s see if its highlights can attract you with Xiaobian.

Let’s look at the appearance of Baojun Yueye first. The design of Baojun Yueye’s front is very simple and sporty. Coupled with the fashionable headlights, the overall look has a certain sense of hierarchy. The car is equipped with LED daytime running lights, automatic opening and closing, delayed closing and so on. Coming to the side of the car body, the size of the car body is 3381 mm * 1685 mm * 1721 mm. The car adopts capable lines, giving people a very young and fashionable feeling. With large-sized thick-walled tires, the overall visual effect is very fashionable and simple. In terms of the rear end, the overall shape of the rear end echoes the front face, and the taillights present a fashionable and atmospheric design style, which is very cool.

Sitting in the car, Bao Junyue’s interior looks very avant-garde and the visual effect is very good. The steering wheel shape of the car is eye-catching, made of leather, and its practicality and face value are not bad. Let’s take a look at the central control. The car is equipped with a sleek and lovely touch-sensitive LCD central control screen, which makes the interior design quite layered, and the overall design of the central control is remarkable. The dashboard and seats give people a good feeling, too. Let’s take a look. The dashboard design is remarkable and looks very tough. The car uses leather seats, equipped with functions such as electric adjustment of auxiliary seats, electric adjustment of seats, and tilting of seats, which has good support and comfort.

Bao Junyue is also equipped with a motor with a total power of 50KW and a total torque of 140N.m, which has good acceleration, excellent cruising range and good power performance.

The car is equipped with driving mode selection, remote control key, Bluetooth key, traction control (ASR/TCS, etc.), Bluetooth /WIFI connection, full-speed adaptive cruise and other configurations, and the configuration has reached the mainstream level of the same level.

This class of cars can often give consideration to both cost performance and practicality, and is often considered by most consumers as the first choice when buying a car. If you just need such a travel tool, you may wish to experience it quickly.

[Understand the way of the car, smell the car every day] Let’s take stock of what major events happened in the automotive industry on September 13, 2022.

Automotive Event 1: Volvo Registers Electric Vehicle Trademark

The next generation of Volvo XC90 is rumored to be called "Embla" – a way of doing away with the letter and number naming rules Volvo has used on cars for decades – and now Volvo is planning a series of new names for all-electric products.

The European Union Intellectual Property Office has revealed a series of patent applications, and Volvo appears to be planning to replace its current model lineup with pure electric models. It doesn’t look like the new naming scheme will change much to the structure of the current lineup, such as the EXC90, EXC60, EXC40 and EC40, etc. These are likely to be pure electric versions of the current SUV lineup. The same is true for Volvo’s sedans and wagons, such as the ES60, ES90, EV60 and EV90 are already registered.

Not only that, but we have also seen Volvo register trademarks for the EX30, EX40, EX60 and EX90. This move does not rule out Volvo’s intention to bring these products into production. Currently, Volvo’s new SPA2 platform can accommodate all-electric vehicles from the S60 to the XC90.

It is worth noting that Volvo previously announced that it will transform into a pure electric luxury car company by 2030, and Volvo plans to achieve the global sales target of 1.20 million vehicles by 2025, of which at least 50% will be pure electric vehicles.

Automotive incident 2: Changsha BYD chip production line completed installation

A few days ago, we learned from Hunan Daily that Changsha BYD Semiconductor Co., Ltd.’s 8-inch automotive chip production line successfully completed the installation on September 5 and began production debugging. It is expected to be officially put into production in early October and can produce car-grade chips 500,000.

BYD Automobile released a sales report for August. Data show that BYD’s car sales in August were 174,915 units, an increase of 155.2% year-on-year. Specifically, BYD’s car passenger car sales in August were 173,977 units, an increase of 157.2% year-on-year. Among them, BYD’s DM model sales were 91,299 units, and EV model sales were 82,678 units.

Auto Incident 3: Lantu Auto Officially Reveals Capital Increase Information

A few days ago, the information of Lantu Auto’s capital increase project was officially disclosed on the Shanghai United Equity Exchange. This capital increase is the first external equity financing since the establishment of Lantu Auto. It will further optimize the equity structure of Lantu Auto, stimulate the vitality of the enterprise market, and accelerate the reform process of the system and mechanism of state-owned enterprises.

Before the capital increase, 89.66% of Lantu Automobile was held by Dongfeng Motor Group’s joint stock company (referred to as "Dongfeng Group"), and 10.34% was held by Wuhan Waya Enterprise Management Consulting Partnership (Limited Partnership) (referred to as "Employee Stock Ownership Platform"). After this round of capital increase, it is expected that Dongfeng Group will hold no less than 77% of the equity, strategic investors will hold no more than 15% of the total equity, and the employee stock ownership platform will hold no less than 8% of the equity.

Auto Event 4: SIA assesses investor demand for $2 billion IPO

Recently, according to domestic media reports, power battery manufacturer China Innovation New Airlines has begun to evaluate investor demand for its 2 billion US dollars (about 13.853 billion yuan) IPO plan after hearing through the Hong Kong Stock Exchange, from September 12 to September 22.

It is understood that the funds raised by SIA through this IPO will be used for the construction and expansion of multiple production bases, research and development, Working Funds and general corporate purposes. In the first quarter of this year, SIA’s revenue was 3.897 billion yuan, compared with 1.063 billion yuan in the same period last year; gross profit was 320 million yuan, compared with 140 million yuan in the same period last year.

"Daily Car News", here are the latest car news of the day, please continue to pay attention to "The Way to Know Your Car".

He is a Chinese mainland film and television actor and pop singer, born on September 20, 1982, from Xuhui District, Shanghai. He graduated from the Performance Department of Shanghai Theater Academy, is a Chinese mainland film and television actor and pop singer, and is also a member of the Democratic League.

Hu Ge’s acting career began in 2004, when he starred in his first TV drama "Dandelion." He then starred as Li Xiaoyao in the 2005 drama "The Legend of the Sword" and sang the episodes "June Rain" and "Xiaoyao Sighs". In the following years, he starred in the TV series "Flying Immortals" (2006), released his debut music album "Departure" (2008), and starred as Sedum in the drama "The Legend of the Sword and the Sword" and sang the ending song "Forgetting Time" (2009).

Hu Ge continued to make breakthroughs in his acting career, starring as Yi Xiaochuan and Meng Yi in the time-travel drama "Myth" (2010), releasing the music album "Blu-ray", and being nominated for the Best Newcomer Award in the Popular Film Hundred Flowers Award in the historical film "Revolution of 1911" (2011).

Since then, Hu Ge’s acting career has reached a new level. He played Yu Wentuo in the fantasy drama "Xuanyuan Sword Sky Mark" (2012), and won the Best Actor Award at the 2nd Beijing Danny International Stage Performing Arts Awards in the drama "Dream Like a Dream" (2013).

Hu Ge played Ming Tai (2015) in the spy drama "The Pretender", and won the Best Actor Award at the 22nd Shanghai TV Festival Magnolia Award for the role of Mei Changsu in the costume drama "Langya Bang", the 28th China TV Golden Eagle Awards Audience Favorite Actor Award, and the 11th China Golden Eagle TV Art Festival Most Popular Actor Award.

In addition to his acting career, Hu Ge is also actively involved in public welfare undertakings. He performed the song "Love Each Other" on the CCTV Spring Festival Gala in 2016.

For more information about Hu Ge, check out entertainment news websites or follow his social media accounts.

Responsible editor:

A large number of innovative drugs and "life-saving drugs" have entered the medical insurance drug list, which is the space saved by centralized procurement.

　 　 　 　On December 6, 2018, the centralized procurement of drugs in "4+7" pilot cities was opened in Shanghai. This means that the long-brewing national drug centralized procurement with quantity has officially kicked off.

National centralized drug procurement with quantity, referred to as "centralized procurement" for short, means that drug procurement institutions "package" the scattered purchases of medical institutions through public bidding, and purchase a clear number of drugs from drug suppliers by "group purchase", thus reducing procurement costs.

　 　 　 　At that time, the national medical insurance department entrusted the Shanghai Pharmaceutical Centralized Bidding and Purchasing Affairs Management Office under the Shanghai Medical Insurance Bureau to undertake the daily work of the national drug joint purchasing office (hereinafter referred to as "joint purchasing"). In the past three years, the joint procurement has organized six batches and seven rounds of national centralized procurement, and the scope of implementation has expanded from 11 cities to the whole country. The procurement content has expanded from oral dosage forms to injections, from chemical drugs to biological drugs, and the variety, quantity and degree of competition have been constantly breaking through.

　 　 　 　Specifically, what are the breakthroughs?Let’s take a look at the changes in these three years through the data.

The original drug was greatly reduced in price, and the "patent cliff" appeared.

　 　 　 　Among the six batches and seven rounds of centralized mining, the first five batches and six rounds are all chemical drugs. From the first batch of "4+7 quantity procurement" to the fifth batch of quantity procurement,A total of 218 varieties were covered, and the average price of the selected products decreased by 53%, which reduced the burden on patients by about 250 billion yuan.

　 　 　 　The number of selected products shows an upward trend.In the "4+7 quantity procurement", 25 of the 31 pilot generic drugs were successfully selected, with a successful selection rate of 81%. Since then, the number of selected varieties has reached 32, 55, 45 and 61 respectively. The sixth batch of insulin special procurement is the first time that the national centralized procurement has been extended to the field of biopharmaceuticals, which is quite different from the first five batches of procurement rules, and the number of selected varieties is 16.

　 　 　 　Except for the sixth batch of insulin special procurement, the average decline of the other five batches and six rounds of centralized procurement was above 50%, which remained stable. The fifth batch of centralized mining decreased by 56%, which was higher than other batches. It can be clearly seen that the centralized collection and extrusion of drug price moisture has played a positive role in promoting the return of drug prices to rationality.

　 　 　 　Centralized purchasing not only reduces the burden of drug use for the masses, but also improves the efficiency of the use of medical insurance funds.After calculation, the results of each batch of bidding saved 5.8 billion yuan, 19.5 billion yuan, 9.1 billion yuan, 19.5 billion yuan, 13.2 billion yuan, 24.1 billion yuan and 9 billion yuan for the pilot areas or the whole country. Among them, the fifth batch of centralized procurement selected the most varieties, involving a total amount of 55 billion yuan, saving medicine costs to the highest in previous centralized procurement.

　 　 　 　As a result, has the medical insurance expenditure decreased? Where did all the money saved go? In fact, to improve the efficiency of the use of medical insurance funds is not only to "cut costs", but also to spend money on the cutting edge. In recent years, a large number of innovative drugs and "life-saving drugs" have entered the medical insurance drug list, which is the space saved by centralized procurement. The continuous increase of medical insurance expenditure has prompted pharmaceutical enterprises to intensify innovation and promoted the process of high-quality development of the pharmaceutical industry.

　 　 　 　The participation and winning bid rate of each batch of original research pharmaceutical companies have always been the focus of attention. Although the average decline of the selected original drugs in the first four batches of centralized procurement was relatively high, climbing from 71% and 79% to 82% and 84%, there were 10 foreign companies involved in 11 products in the fifth batch of centralized procurement, and their participation was significantly improved.

　 　 　 　Foreign companies actively embrace centralized purchasing. On the one hand, the fifth batch of centralized purchasing involves many kinds of injections, and the successful result will have a great impact on the sales of enterprises in hospitals. Faced with such a big market change, foreign companies can’t "sit idly by". More importantly, it has been gradually accepted by the industry and society because the original drug is equivalent in quality and can compete on the same field. This is the embodiment of the implementation effect of the generic drug consistency evaluation policy and the embodiment of the normalization and institutionalization of centralized purchase.

　 　 　 　More and more original drugs have been greatly reduced in price, indicating that the phenomenon of "patent cliff" has appeared.The so-called "patent cliff" means that after the patent protection of a newly developed and listed drug expires, more generic drugs will appear on the market, and the increase in supply will lead to a cliff-like decline in the price of the original drug. In the past, the prices of some original drugs in China were higher than those in neighboring countries and regions for a long time, and the phenomenon of "patent cliff" failed to happen. Now, this phenomenon has finally happened because of national centralized mining.

"Taking quantity" is the core, and promoting "exchanging quantity for price"

　 　 　 　Six batches of centralized mining, which drug varieties have the highest decline?Based on the 457 drugs with known historical prices, the top drugs have different uses. Rivaroxaban, an anticoagulant in the fifth batch of centralized mining, dropped by as much as 99.5%, which is a veritable "price reduction king". Memantine for the treatment of Alzheimer’s Harmo’s disease and olanzapine for the treatment of schizophrenia are also in the forefront with a drop of over 97%. Taking olanzapine orally disintegrating tablets as an example, patients used to spend 849 yuan a month, but now they can save 822 yuan by using the selected varieties, which can save more than 9,000 yuan a year.

　 　 　 　Some time ago, the "soul bargaining" in the national medical insurance drug list negotiation triggered a heated discussion. Is collective purchasing "soul bargaining"? In fact,Centralized purchasing and medical insurance negotiation are two different things.Although both of them belong to the "drug price reduction" initiative, the medical insurance negotiation is to include drugs in the catalogue, so that they can be reimbursed through medical insurance, and there is no provision for hospital dosage; Centralized procurement requires hospitals to give priority to the use of selected drugs and complete the contract dosage on time. It can be said that "with or without quantity" is the main difference between the two. In addition, the drugs selected in centralized procurement include both varieties in the medical insurance catalogue and those outside the catalogue.

　 　 　"Carrying quantity" is the core of centralized purchasing, and "exchanging quantity for price" can promote enterprises to reduce prices. So,What are the ten varieties with the largest purchase volume?It can be seen from the agreed procurement volume in the first year of the country that the drugs for common diseases, such as hypertension and hyperlipidemia, are still in the greatest demand, among which metformin for treating type 2 diabetes has the largest procurement volume, with the agreed procurement volume reaching more than 5 billion tablets in the first year, and the actual procurement volume in the first year of the country exceeds 8 billion tablets. 2021 is the 100th anniversary of the discovery of insulin, and insulin has been continuously introduced in the past 100 years. At present, the second generation of recombinant human insulin and the third generation of recombinant insulin analogues are commonly used products in clinic. Relatively speaking, the third-generation insulin is safer and more effective, and the price is higher.

　 　 　 　Just at the end of last month, the sixth batch of centralized purchase of insulin was opened in Shanghai. This collection covers the second and third generations of insulin, including 16 generic varieties. The purchasing demand of medical institutions in China in the first year is about 210 million pieces, and the purchasing amount involved is about 17 billion yuan according to the pre-centralized purchasing price. The average price reduction of the products to be selected is 48%, and it is estimated that the annual cost can be saved by 9 billion yuan.

　 　 　 　The three years that Ji Cai has gone through are three years of challenges and achievements. The "Tenth Five-Year Plan" for National Medical Security proposes that by the end of the "Tenth Five-Year Plan", the number of drug varieties purchased by each province through national and provincial centralized quantity will reach more than 500. Practice has proved that only by holding on to the reform achievements and constantly promoting the normalization and institutionalization of centralized drug procurement can we better serve the overall situation of national medical and health reform and development and provide people with all-round and full-cycle health services.　 　　　

◆ Source | Jiefang Daily/China Medical Insurance